Optometry Marketing Compliance: Contact Lens Rules, Dry Eye Treatment Claims, and Myopia Management Marketing
Optometry marketing combines retail optical rules, FDA device considerations, FTC contact lens rules, and specific claim categories like dry eye treatment and myopia management. Here's the framework.
Optometry practices operate under a distinct mix of compliance rules: state optometry licensing boards, the FTC Contact Lens Rule (which specifically governs contact lens sales), FDA device considerations for various treatments, and specific claim-category rules for dry eye treatment and myopia management marketing. The retail optical layer adds consumer-product rules on top.
The FTC Contact Lens Rule
The FTC Contact Lens Rule (16 CFR Part 315) regulates contact lens prescriptions and sales. Marketing implications:
- Prescriptions must be provided to patients automatically after eye exams; marketing cannot imply prescriptions are optional or additional-fee services.
- Automatic-refill programs and subscription models need specific disclosure.
- Pricing marketing for exam services shouldn’t bundle prescription release with service charges.
- Online contact lens retailers face specific rules about prescription verification.
Dry eye treatment marketing
Dry eye treatment is one of the fastest-growing optometry service categories. Compliance considerations:
- Specific treatment claims (IPL, LipiFlow, punctal plugs, prescription eye drops) need substantiation matching the specific device or treatment.
- FDA-cleared vs FDA-approved distinction applies to devices (most dry eye devices are cleared).
- Claims about specific outcomes (improved tear production, specific symptom resolution timelines) need substantiation.
Myopia management marketing
Myopia management (orthokeratology, low-dose atropine, special contact lenses, behavioral interventions) is a growing pediatric service line.
- Specific myopia-progression-slowing claims need published evidence supporting the specific intervention.
- Atropine is off-label for myopia management in most circumstances; marketing should reflect this.
- Pediatric marketing considerations apply (see pediatric practice marketing compliance post).
Refractive surgery marketing
LASIK, PRK, SMILE, and ICL marketing follows general surgical marketing framework. Specific issues:
- Outcome promises (20/20 vision guaranteed) are unsubstantiable.
- Pricing marketing should clearly disclose total cost.
- Candidacy-specific outcomes should be framed individually.
- Comparison between refractive surgery types needs substantiation.
State optometry board rules
State optometry boards have varying advertising rules and scope-of-practice rules (some states allow broader treatment including minor surgery, others more restricted). Marketing should match actual scope.
Retail optical considerations
Optical retail (frames, lenses, sunglasses) adds consumer-product marketing rules on top of the clinical layer:
- Pricing disclosure for packages (frames + lenses + coatings).
- Brand-name lens marketing.
- Guarantee and warranty language.
Compliant optometry marketing framework
- FTC Contact Lens Rule compliance.Especially for practices selling contacts.
- Accurate FDA device status. Cleared vs approved, specific indications.
- Service-and-examination-forward framing.Consultation and comprehensive examination as the entry point.
- Conservative outcome framing for refractive surgery.Most patients achieve significant vision improvement; individual outcomes vary.
- Accurate scope-of-practice representation.State-specific for treatment services.
Frequently asked questions
Does the FTC Contact Lens Rule apply to my practice?
If you prescribe or sell contact lenses, yes. The Rule covers prescribers and sellers. Specific compliance requirements include automatic prescription release and verification procedures for online sales.
Can I market specific LASIK outcome percentages?
With substantiation from specific device clinical data. Practice-specific outcome claims need your actual outcome data. General “99% satisfaction” marketing is typically unsubstantiable.
What about dry eye treatment device marketing?
Accurate FDA-cleared status, specific labeled indications, published clinical evidence for specific claims. Most dry eye devices are cleared for specific indications; marketing within those is generally fine.
How should I market myopia management to parents?
With substantiation for specific interventions and honest framing of the evidence state. Different myopia management approaches have different evidence bases; accurate representation matters.
What about online eye exam marketing?
Online refraction services face specific FTC and state board attention. Marketing should accurately represent what online services can and cannot provide, and the role of in-person examination.
What documentation should optometry practices maintain?
Contact Lens Rule compliance records, device FDA clearance documentation, substantiation for efficacy claims, state scope-of-practice documentation, and standard healthcare marketing records.
Built for this exact problem
Scan your clinic's content before regulators do.
RegenCompliance checks every word of your marketing against live FDA and FTC enforcement data - and rewrites violations automatically. A 30-second scan can save a $50,000–$5M regulatory response.
Related in the platform
Weekly compliance brief
One email a week. New enforcement actions, rule changes, and tactical fixes. No spam, unsubscribe anytime.
Keep reading
Compounded GLP-1 Marketing Compliance in 2026: What Changed When the Shortage List Closed
When the FDA declared the semaglutide and tirzepatide shortages resolved, the legal basis for routine 503A compounding narrowed. Your existing compounded-GLP-1 marketing was probably written for the old posture. Here is the 2026 rewrite.
Read articleKetamine Clinic Marketing Compliance Guide: IV Ketamine for Depression Without Triggering an FDA Letter
Most ketamine clinic marketing problems are not exotic - they are six or seven repeated phrases that the FDA October 2023 communication and 2024 enforcement actions have already singled out. This guide focuses on the IV ketamine for depression use case and rewrites the patterns that get clinics in trouble.
Read articleNAD+ IV Therapy Marketing and the FDA Position: What Actually Has Approval, What Does Not, and How to Word It
Most NAD+ IV therapy marketing trouble is upstream of the FTC longevity-claim issue. It is the quiet implication that NAD+ has some kind of FDA status it does not have. Here is the actual FDA position and how to word a NAD+ program page around it.
Read article